It is caused by a variety of viral pathogens with human rhinoviruses (HRV) being the most abundant ones. Larger trials are indicated to confirm the results.Ĭommon cold is the most prevalent contagious viral disease in humans. Iota-Carrageenan nasal spray appears to be a promising treatment for safe and effective treatment of early symptoms of common cold. Pro-inflammatory mediators FGF-2, Fractalkine, GRO, G-CSF, IL-8, IL-1α, IP-10, IL-10, and IFN-α2 were reduced in the Iota-Carrageenan group. ResultsĪdministration of Iota-Carrageenan nasal spray reduced the symptoms of common cold (p = 0.046) and the viral load in nasal lavages (p = 0.009) in patients with early symptoms of common cold. In a randomized, double-blind, placebo-controlled exploratory trial, 35 human subjects suffering from early symptoms of common cold received Iota-Carrageenan (0.12%) in a saline solution three times daily for 4 days, compared to placebo.
This study investigated the efficacy and safety of an Iota-Carrageenan nasal spray in patients with common cold symptoms. Iota-Carrageenan is broadly active against respiratory viruses in-vitro and has an excellent safety profile. For more information, please visit common cold, the most prevalent contagious viral disease in humans still lacks a safe and effective antiviral treatment. Amcyte’s pipeline includes cytokines and immunomodulators that enhance the activity of new cell therapy treatments as well as targets for orphan diseases with affordable and improved therapeutic profiles against existing treatments. The company has built strong partnerships with leading academic institutions and clinical groups to develop novel indications for its portfolio of products. The safety of Nasitrol has been well established and the product has been approved by The Administración Nacional de Medicamentos, Alimentos y Tecnología Médica of the Argentine Republic and commercialized by Laboratorio Pablo Cassara for the prevention of common cold for a decade.Īmcyte’s team has over 20 years of experience in cytokine and immunomodulator development and manufacturing. The Nasitrol formulation is designed to reduce the viral load in upper respiratory airways, preventing viruses from proliferating and spreading into the lungs. Iota-carrageenan is thought to exert antiviral activity through its interaction with the viral surface, preventing viral entry and capturing viral particles released by infected cells. The nasal cavity and the rhinopharynx are key sites of the initial replication of SARS-CoV-2. so that healthcare professionals, caregivers for COVID patients and other individuals who are at risk can benefit.” “We look forward to partnering and commercializing Nasitrol in the U.S. “This rigorous, placebo-controlled study provides evidence that the simple intervention of a nasal spray with iota-carrageenan, in addition to hand hygiene, use of personal protective equipment and social distancing, could provide additional protection against transmission,” said Dr. Mónica Lombardo of the CEMIC University Hospital in Buenos Aires, and sponsored by the Ministry of Science, Technology and Innovation of Argentina. Figueroa of The Cesar Milstein Research Institute in Argentina and Dr. There were no differences in the incidence of adverse events between the two groups. The incidence of COVID-19 infection was significantly lower in the Nasitrol group compared with placebo (1.0% vs 5.0%). The primary end point was clinical COVID-19 infection, as confirmed by reverse-transcriptase-polymerase-chain-reaction testing, over a period of 21 days. Study subjects were randomly assigned to receive four daily doses of Nasitrol spray or placebo for 21 days. The current study was conducted at 8 hospital ICUs with a sample of 394 clinically healthy physicians, nurses and other medical professionals who provided care to COVID patients and who had not yet been vaccinated against the disease.
A previous study at the University of Tennessee Health Science Center found that the iota carrageenan formulation inhibits infection by SARS-CoV-2, the virus that causes COVID-19, in cell culture in vitro. Nasitrol is a patented nasal spray based on iota carrageenan, a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as a nasal spray in the treatment of the common cold. through a licensing agreement from Laboratorio Pablo Cassara, an Argentinean pharma company leader in innovation.
#Iota carrageenan nasal spray trial
KIRKLAND, Wash.-( BUSINESS WIRE)-Amcyte Pharma, a Seattle-based company dedicated to the commercialization of immunomodulators, announced the results of an independent clinical trial among ICU staff suggesting that its product, Nasitrol TM nasal spray, represents a safe and effective treatment that could prevent transmission of COVID-19.
0 kommentar(er)
